Antimicrobial Treatment of Pseudomonas aeruginosa Severe Sepsis
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Pseudomonas aeruginosa is a pathogen often encountered in a healthcare setting. It has consistently ranked among the most frequent pathogens seen in nosocomial infections, particularly bloodstream and respiratory tract infections. Aside from having intrinsic resistance to many antibiotics, it rapidly acquires resistance to novel agents. Given the high mortality of pseudomonal infections generally, and pseudomonal sepsis particularly, and with the rise of resistant strains, treatment can be very challenging for the clinician. In this paper, we will review the latest evidence for the optimal treatment of P. aeruginosa sepsis caused by susceptible as well as multidrug-resistant strains including the difficult to treat pathogens. We will also discuss the mode of drug infusion, indications for combination therapy, along with the proper dosing and duration of treatment for various conditions with a brief discussion of the use of non-antimicrobial agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The overuse and misuse of antibiotics in both healthcare and agriculture have accelerated the emergence of MDR strains, representing a significant global threat to human health, underscoring the urgent need for novel therapeutic strategies [2, 3].”
From Exploring the antibacterial and anti-biofilm activity of two Iranian medical-grade kinds of honey on multidrug-resistant Pseudomonas aeruginosa (2025) · cites this paper as [2]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Magiorakos, A.-P., Srinivasan, A., Carey, R. B., Carmeli, Y., Falagas, M. E., Giske, C. G., Harbarth, S., Hindler, J. F., Kahlmeter, G., Olsson-Liljequist, B., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03570.x · Cited by 14,449 · cited 1×
“aeruginosa, MDR is defined as resistance to at least one agent in three or more antibiotic classes, extensive drug resistance (XDR) is defined as resistance to at least one agent in all but two or fewer antibiotic classes, and pan-drug resistance (PDR) is non-susceptibility to all agents [32].”
BackgroundMultistate point-prevalence survey of health care-associated infections
Magill, S. S., Edwards, J. R., Bamberg, W., Beldavs, Z. G., Dumyati, G., Kainer, M. A., Lynfield, R., Maloney, M., McAllister-Hollod, L., Nadle, J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1306801 · Cited by 3,931
Surviving Sepsis Campaign: International guidelines for management of sepsis and septic shock: 2016.
Rhodes, A., Evans, L. E., Alhazzani, W., Levy, M. M., Antonelli, M., Ferrer, R., Kumar, A., Sevransky, J. E., Sprung, C. L., Nunnally, M. E., et al. (2017) · Critical Care Medicine · doi:10.1097/ccm.0000000000002255 · Cited by 3,652
Tamma, P. D., Aitken, S. L., Bonomo, R. A., Mathers, A. J., van Duin, D., & Clancy, C. J. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad428 · Cited by 740
Multidrug-resistant bacterial infections in U.S. hospitalized patients, 2012-2017.
Jernigan, J. A., Hatfield, K. M., Wolford, H., Nelson, R. E., Olubajo, B., Reddy, S. C., McCarthy, N., Paul, P., McDonald, L. C., Kallen, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1914433 · Cited by 577
Antibiotics in critically ill patients: A systematic review of the pharmacokinetics of β-lactams.
Gonçalves-Pereira, J., & Póvoa, P. (2011) · Critical Care · doi:10.1186/cc10441 · Cited by 408
Vardakas, K. Z., Voulgaris, G. L., Maliaros, A., Samonis, G., & Falagas, M. E. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30615-1 · Cited by 327
Pugh, R., Grant, C., Cooke, R. P., & Dempsey, G. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007577.pub3 · Cited by 289
Tansarli, G. S., Andreatos, N., Pliakos, E. E., & Mylonakis, E. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02495-18 · Cited by 56
Research works printed but not linked: 148
- Fosse, 2018, Combination therapy for treatment of Pseudomonas aeruginosa bloodstream infections, PLoS ONE, 13, e0203295, 10.1371/journal.pone.0203295 · DOI
- Horino, 2012, Clinical characteristics and risk factors for mortality in patients with bacteremia caused by Pseudomonas aeruginosa, Intern. Med. Tokyo Jpn., 51, 59, 10.2169/internalmedicine.51.5698 · DOI
- Kang, 2003, Pseudomonas aeruginosa Bacteremia: Risk Factors for Mortality and Influence of Delayed Receipt of Effective Antimicrobial Therapy on Clinical Outcome, Clin. Infect. Dis., 37, 745, 10.1086/377200 · DOI · Paper page
- Thaden, 2017, Results from a 13-Year Prospective Cohort Study Show Increased Mortality Associated with Bloodstream Infections Caused by Pseudomonas aeruginosa Compared to Other Bacteria, Antimicrob. Agents Chemother., 61, e02671-16, 10.1128/AAC.02671-16 · DOI · Paper page
- Cattaneo, 2012, P. aeruginosa bloodstream infections among hematological patients: An old or new question?, Ann. Hematol., 91, 1299, 10.1007/s00277-012-1424-3 · DOI
- Tofas, 2017, Pseudomonas aeruginosa bacteraemia in patients with hematologic malignancies: Risk factors, treatment and outcome, Diagn. Microbiol. Infect. Dis., 88, 335, 10.1016/j.diagmicrobio.2017.05.003 · DOI
- Botelho, 2019, Antibiotic resistance in Pseudomonas aeruginosa—Mechanisms, epidemiology and evolution, Drug Resist. Updates, 44, 100640, 10.1016/j.drup.2019.07.002 · DOI · Paper page
- Babich, 2020, Risk factors for mortality among patients with Pseudomonas aeruginosa bacteraemia: A retrospective multicentre study, Int. J. Antimicrob. Agents, 55, 105847, 10.1016/j.ijantimicag.2019.11.004 · DOI
- Albasanz-Puig, A., Durà-Miralles, X., Laporte-Amargós, J., Mussetti, A., Ruiz-Camps, I., Puerta-Alcalde, P., Abdala, E., Oltolini, C., Akova, M., and Montejo, J.M. (2022). Effect of Combination Antibiotic Empirical Therapy on Mortality in Neutropenic Cancer Patients with Pseudomonas aeruginosa Pneumonia. Microorganisms, 10. · DOI
- Nakamura, 2013, Meropenem as predictive risk factor for isolation of multidrug-resistant Pseudomonas aeruginosa, J. Hosp. Infect., 83, 153, 10.1016/j.jhin.2012.10.005 · DOI
- Aloush, 2006, Multidrug-resistant Pseudomonas aeruginosa: Risk factors and clinical impact, Antimicrob. Agents Chemother., 50, 43, 10.1128/AAC.50.1.43-48.2006 · DOI · Paper page
- Mendelson, 1994, Pseudomonas aeruginosa bacteremia in patients with AIDS, Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am., 18, 886, 10.1093/clinids/18.6.886 · doi:10.1093/clinids/18.6.886
- Flores, 1993, Bacteremia due to Pseudomonas aeruginosa in children with AIDS, Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am., 16, 706, 10.1093/clind/16.5.706 · doi:10.1093/clind/16.5.706
- Zidaru, 2022, Clinical outcomes of cystic fibrosis patients with Pseudomonas aeruginosa bloodstream infection, J. Glob. Antimicrob. Resist., 29, 551, 10.1016/j.jgar.2021.12.004 · doi:10.1016/j.jgar.2021.12.004
- Micek, 2015, An international multicenter retrospective study of Pseudomonas aeruginosa nosocomial pneumonia: Impact of multidrug resistance, Crit. Care Lond. Engl., 19, 219, 10.1186/s13054-015-0926-5 · DOI · Paper page
- Tumbarello, 2013, Clinical outcomes of Pseudomonas aeruginosa pneumonia in intensive care unit patients, Intensive Care Med., 39, 682, 10.1007/s00134-013-2828-9 · DOI · Paper page
- Bassetti, 2018, How to manage Pseudomonas aeruginosa infections, Drugs Context, 7, 212527, 10.7573/dic.212527 · DOI · Paper page
- Jabbour, 2020, Treatment of multidrug-resistant Gram-negative skin and soft tissue infections, Curr. Opin. Infect. Dis., 33, 146, 10.1097/QCO.0000000000000635 · DOI
- Ibrahim, 2020, Current choices of antibiotic treatment for Pseudomonas aeruginosa infections, Curr. Opin. Infect. Dis., 33, 464, 10.1097/QCO.0000000000000677 · DOI
- Herrera, 2021, Predictors of multidrug resistant Pseudomonas aeruginosa involvement in bloodstream infections, Curr. Opin. Infect. Dis., 34, 686, 10.1097/QCO.0000000000000768 · DOI
- Forkner, 1958, Pseudomonas septicemia; observations on twenty-three cases, Am. J. Med., 25, 877, 10.1016/0002-9343(58)90060-3 · doi:10.1016/0002-9343(58)90060-3
- Bassetti, 2016, Bloodstream infections in the Intensive Care Unit, Virulence, 7, 267, 10.1080/21505594.2015.1134072 · DOI
- Kaye, 2013, Carbapenem-resistant Enterobacteriaceae: A review of treatment and outcomes, Diagn. Microbiol. Infect. Dis., 75, 115, 10.1016/j.diagmicrobio.2012.11.009 · DOI · Paper page
- Falcone, 2020, Time to appropriate antibiotic therapy is a predictor of outcome in patients with bloodstream infection caused by KPC-producing Klebsiella pneumoniae, Crit. Care Lond. Engl., 24, 29, 10.1186/s13054-020-2742-9 · DOI · Paper page
- Kaprou, G.D., Bergšpica, I., Alexa, E.A., Alvarez-Ordóñez, A., and Prieto, M. (2021). Rapid Methods for Antimicrobial Resistance Diagnostics. Antibiotics, 10. · DOI · Paper page
- Bassetti, 2018, Rational approach in the management of Pseudomonas aeruginosa infections, Curr. Opin. Infect. Dis., 31, 578, 10.1097/QCO.0000000000000505 · DOI
- Rosenthal, 2016, International Nosocomial Infection Control Consortium report, data summary of 50 countries for 2010-2015: Device-associated module, Am. J. Infect. Control, 44, 1495, 10.1016/j.ajic.2016.08.007 · DOI · Paper page
- Kadri, 2018, Difficult-To-Treat Resistance in Gram-Negative Bacteremia at 173 US Hospitals: Retrospective Cohort Analysis of Prevalence, Predictors, and Outcome of Resistance to All First-Line Agents, Clin. Infect. Dis., 67, 1803
- Paul, 2022, European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine), Clin. Microbiol. Infect., 28, 521, 10.1016/j.cmi.2021.11.025 · DOI · Paper page
- Mulet, 2018, Ceftolozane/tazobactam for the treatment of multidrug resistant Pseudomonas aeruginosa: Experience from the Balearic Islands, Eur. J. Clin. Microbiol. Infect. Dis., 37, 2191, 10.1007/s10096-018-3361-0 · DOI
- Vardakas, 2013, β-Lactam plus aminoglycoside or fluoroquinolone combination versus β-lactam monotherapy for Pseudomonas aeruginosa infections: A meta-analysis, Int. J. Antimicrob. Agents, 41, 301, 10.1016/j.ijantimicag.2012.12.006 · DOI
- Paul, 2014, Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis, Cochrane Database Syst. Rev., 2014, CD003344
- Peña, C., Suarez, C., Ocampo-Sosa, A., Murillas, J., Almirante, B., Pomar, V., Aguilar, M., Granados, A., Calbo, E., and Rodríguez-Baño, J. (2013). Effect of Adequate Single-Drug vs Combination Antimicrobial Therapy on Mortality in Pseudomonas aeruginosa Bloodstream Infections: A Post Hoc Analysis of a Prospective Cohort. Clinical Infectious Diseases, Oxford Academic. Available online: https://academic.oup.com/cid/article/57/2/208/313652. · DOI · Paper page
- Onorato, 2022, Beta-lactam monotherapy or combination therapy for bloodstream infections or pneumonia due to Pseudomonas aeruginosa: A meta-analysis, Int. J. Antimicrob. Agents, 59, 106512, 10.1016/j.ijantimicag.2021.106512 · DOI
- Micek, 2005, Pseudomonas aeruginosa bloodstream infection: Importance of appropriate initial antimicrobial treatment, Antimicrob. Agents Chemother., 49, 1306, 10.1128/AAC.49.4.1306-1311.2005 · DOI · Paper page
- Fiore, M., Corrente, A., Pace, M.C., Alfieri, A., Simeon, V., Ippolito, M., Giarratano, A., and Cortegiani, A. (2022, July 31). Ceftolozane-Tazobactam Combination Therapy Compared to Ceftolozane-Tazobactam Monotherapy for the Treatment of Severe Infections: A Systematic Review and Meta-Analysis, Available online: https://pubmed.ncbi.nlm.nih.gov/33467508/. · doi:10.3390/antibiotics10010079
- Bassetti, 2020, Management of infections caused by WHO critical priority Gram-negative pathogens in Arab countries of the Middle East: A consensus paper, Int. J. Antimicrob. Agents, 56, 106104, 10.1016/j.ijantimicag.2020.106104 · DOI
- Paulsson, 2017, Antimicrobial combination treatment including ciprofloxacin decreased the mortality rate of Pseudomonas aeruginosa bacteraemia: A retrospective cohort study, Eur. J. Clin. Microbiol. Infect. Dis., 36, 1187, 10.1007/s10096-017-2907-x · doi:10.1007/s10096-017-2907-x
- Puzniak, 2019, A Combination Antibiogram Evaluation for Pseudomonas aeruginosa in Respiratory and Blood Sources from Intensive Care Unit (ICU) and Non-ICU Settings in U.S. Hospitals, Antimicrob. Agents Chemother., 63, e02564-18, 10.1128/AAC.02564-18 · DOI
- Wauters, 2018, Higher versus standard amikacin single dose in emergency department patients with severe sepsis and septic shock: A randomised controlled trial, Int. J. Antimicrob. Agents, 51, 562, 10.1016/j.ijantimicag.2017.11.009 · DOI
- Moise, 2021, Collective assessment of antimicrobial susceptibility among the most common Gram-negative respiratory pathogens driving therapy in the ICU, JAC-Antimicrob. Resist., 3, dlaa129, 10.1093/jacamr/dlaa129 · DOI
- Britt, 2018, Importance of Site of Infection and Antibiotic Selection in the Treatment of Carbapenem-Resistant Pseudomonas aeruginosa Sepsis, Antimicrob. Agents Chemother., 62, e02400-17, 10.1128/AAC.02400-17 · DOI
- Kaye, 2006, Differential Effects of Levofloxacin and Ciprofloxacin on the Risk for Isolation of Quinolone-Resistant Pseudomonas aeruginosa, Antimicrob. Agents Chemother., 50, 2192, 10.1128/AAC.00060-06 · DOI
- McKeage, 2015, Finafloxacin: First global approval, Drugs, 75, 687, 10.1007/s40265-015-0384-z · doi:10.1007/s40265-015-0384-z
- Kocsis, B., Gulyás, D., and Szabó, D. (2021). Delafloxacin, Finafloxacin, and Zabofloxacin: Novel Fluoroquinolones in the Antibiotic Pipeline. Antibiotics, 10. · DOI
- Gimeno, 2010, Grupo Español de Estudio de Doripenem [Comparative activity of doripenem, meropenem, and imipenem in recent clinical isolates obtained during the COMPACT-Spain epidemiological surveillance study], Rev. Espanola Quimioter. Publicacion Of. Soc. Espanola Quimioter., 23, 144
- Pillar, 2008, In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States, Antimicrob. Agents Chemother., 52, 4388, 10.1128/AAC.00381-08 · DOI
- Korten, 2011, Comparative evaluation of in vitro activities of carbapenems against gram-negative pathogens: Turkish data of COMPACT study, Mikrobiyol. Bul., 45, 197
- Kanj, 2011, Current Concepts in Antimicrobial Therapy Against Resistant Gram-Negative Organisms: Extended-Spectrum β-Lactamase–Producing Enterobacteriaceae, Carbapenem-Resistant Enterobacteriaceae, and Multidrug-Resistant Pseudomonas aeruginosa, Mayo Clin. Proc., 86, 250, 10.4065/mcp.2010.0674 · DOI · Paper page
- Carmeli, 1999, Emergence of antibiotic-resistant Pseudomonas aeruginosa: Comparison of risks associated with different antipseudomonal agents, Antimicrob. Agents Chemother., 43, 1379, 10.1128/AAC.43.6.1379 · DOI
- Phe, 2019, Outcomes of empiric aminoglycoside monotherapy for Pseudomonas aeruginosa bacteremia, Diagn. Microbiol. Infect. Dis., 93, 346, 10.1016/j.diagmicrobio.2018.10.019 · doi:10.1016/j.diagmicrobio.2018.10.019
- Varghese, J.M., Roberts, J.A., and Lipman, J. (2011). Antimicrobial Pharmacokinetic and Pharmacodynamic Issues in the Critically Ill with Severe Sepsis and Septic Shock-Critical Care Clinics, Elsevier. Available online: https://www.criticalcare.theclinics.com/article/S0749-0704(10)00068-0/fulltext.
- Kluge, 1974, Comparative activity of tobramycin, amikacin, and gentamicin alone and with carbenicillin against Pseudomonas aeruginosa, Antimicrob. Agents Chemother., 6, 442, 10.1128/AAC.6.4.442 · doi:10.1128/aac.6.4.442
- Zhanel, 2012, Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin, Expert Rev. Anti Infect. Ther., 10, 459, 10.1586/eri.12.25 · DOI · Paper page
- Anderson, 2012, Ability of an antibiogram to predict Pseudomonas aeruginosa susceptibility to targeted antimicrobials based on hospital day of isolation, Infect. Control Hosp. Epidemiol., 33, 589, 10.1086/665721 · doi:10.1086/665721
- Riou, 2010, In vivo development of antimicrobial resistance in Pseudomonas aeruginosa strains isolated from the lower respiratory tract of Intensive Care Unit patients with nosocomial pneumonia and receiving antipseudomonal therapy, Int. J. Antimicrob. Agents, 36, 513, 10.1016/j.ijantimicag.2010.08.005 · DOI
- Rodrigues, 2016, Clinical and microbiological features of infections caused by Pseudomonas aeruginosa in patients hospitalized in intensive care units, Rev. Soc. Bras. Med. Trop., 49, 305, 10.1590/0037-8682-0446-2015 · doi:10.1590/0037-8682-0446-2015
- Peng, 2014, Multidrug-resistant Pseudomonas aeruginosa infections pose growing threat to health care–associated infection control in the hospitals of Southern China: A case-control surveillance study, Am. J. Infect. Control, 42, 1308, 10.1016/j.ajic.2014.08.006 · DOI
- Jeong, 2014, Risk factors for mortality in patients with bloodstream infections caused by carbapenem-resistant Pseudomonas aeruginosa: Clinical impact of bacterial virulence and strains on outcome, Diagn. Microbiol. Infect. Dis., 80, 130, 10.1016/j.diagmicrobio.2014.07.003 · DOI
- Torrens, 2016, Activity of Ceftazidime-Avibactam against Clinical and Isogenic Laboratory Pseudomonas aeruginosa Isolates Expressing Combinations of Most Relevant β-Lactam Resistance Mechanisms, Antimicrob. Agents Chemother., 60, 6407, 10.1128/AAC.01282-16 · DOI
- Iregui, 2020, Activity of Cefiderocol Against Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii Endemic to Medical Centers in New York City, Microb. Drug Resist., 26, 722, 10.1089/mdr.2019.0298 · DOI
- Zamorano, 2020, Activity of Imipenem-Relebactam against a Large Collection of Pseudomonas aeruginosa Clinical Isolates and Isogenic β-Lactam-Resistant Mutants, Antimicrob. Agents Chemother., 64, e02165-19, 10.1128/AAC.02165-19 · DOI
- Doi, Y. (2019). Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections. Clinical Infectious Diseases, Oxford Academic. Available online: https://academic.oup.com/cid/article/69/Supplement_7/S565/5623998. · DOI · Paper page
- Kollef, 2019, Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): A randomised, controlled, double-blind, phase 3, non-inferiority trial, Lancet Infect. Dis., 19, 1299, 10.1016/S1473-3099(19)30403-7 · DOI · Paper page
- Solomkin, 2015, Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI), Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am., 60, 1462, 10.1093/cid/civ097 · DOI · Paper page
- Wagenlehner, 2015, Ceftolozane-TAZOBACTAM Compared with Levofloxacin in the Treatment of Complicated Urinary-Tract Infections, Including Pyelonephritis: A Randomised, Double-Blind, Phase 3 Trial (ASPECT-cUTI), Lancet, 385, 1949, 10.1016/S0140-6736(14)62220-0 · DOI · Paper page
- Cabot, 2022, Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa, J. Antimicrob. Chemother., 77, 2809, 10.1093/jac/dkac241 · doi:10.1093/jac/dkac241
- Skoglund, 2018, In Vivo Resistance to Ceftolozane/Tazobactam in Pseudomonas aeruginosa Arising by AmpC- and Non-AmpC-Mediated Pathways, Case Rep. Infect. Dis., 2018, 9095203
- Tamma, 2021, Modifiable Risk Factors for the Emergence of Ceftolozane-tazobactam Resistance, Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am., 73, e4599, 10.1093/cid/ciaa1306 · DOI
- Hamid, 2021, Clinical outcomes, molecular epidemiology and resistance mechanisms of multidrug-resistant Pseudomonas aeruginosa isolated from bloodstream infections from Qatar, Ann. Med., 53, 2345, 10.1080/07853890.2021.2012588 · DOI
- Garazzino, 2020, Ceftolozane/Tazobactam for Treating Children With Exacerbations of Cystic Fibrosis Due to Pseudomonas aeruginosa: A Review of Available Data, Front. Pediatr., 8, 173, 10.3389/fped.2020.00173 · doi:10.3389/fped.2020.00173
- Pfaller, 2021, Ceftolozane-tazobactam activity against clinical isolates of Pseudomonas aeruginosa from ICU patients with pneumonia: United States, 2015–2018, Int. J. Infect. Dis. IJID Off. Publ. Int. Soc. Infect. Dis., 112, 321
- Nichols, 2018, Ceftazidime-Avibactam Susceptibility Breakpoints against Enterobacteriaceae and Pseudomonas aeruginosa, Antimicrob. Agents Chemother., 62, e02590-17, 10.1128/AAC.02590-17 · doi:10.1128/aac.02590-17
- Teo, 2021, Ceftolozane/Tazobactam Resistance and Mechanisms in Carbapenem-Nonsusceptible Pseudomonas aeruginosa, mSphere, 6, e01026-20, 10.1128/mSphere.01026-20 · DOI
- Bassetti, 2021, Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): A randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial, Lancet Infect. Dis., 21, 226, 10.1016/S1473-3099(20)30796-9 · DOI · Paper page
- Motsch, 2020, RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs. Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections, Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am., 70, 1799, 10.1093/cid/ciz530 · DOI · Paper page
- Pogue, 2020, Ceftolozane/Tazobactam vs Polymyxin or Aminoglycoside-based Regimens for the Treatment of Drug-resistant Pseudomonas aeruginosa, Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am., 71, 304, 10.1093/cid/ciz816 · DOI · Paper page
- Karlowsky, 2017, In Vitro Activity of Aztreonam-Avibactam against Enterobacteriaceae and Pseudomonas aeruginosa Isolated by Clinical Laboratories in 40 Countries from 2012 to 2015, Antimicrob. Agents Chemother., 61, e00472-17, 10.1128/AAC.00472-17 · DOI · Paper page
- Lee, 2021, Activity of aztreonam in combination with ceftazidime–avibactam against serine- and metallo-β-lactamase–producing Pseudomonas aeruginosa, Diagn. Microbiol. Infect. Dis., 99, 115227, 10.1016/j.diagmicrobio.2020.115227 · DOI
- Zhanel, 2019, Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli, Drugs, 79, 271, 10.1007/s40265-019-1055-2 · DOI · Paper page
- Kallel, 2006, Colistin as a salvage therapy for nosocomial infections caused by multidrug-resistant bacteria in the ICU, Int. J. Antimicrob. Agents, 28, 366, 10.1016/j.ijantimicag.2006.07.008 · doi:10.1016/j.ijantimicag.2006.07.008
- Hanberger, 2011, When and How to Cover for Resistant Gram-Negative Bacilli in Severe Sepsis and Septic Shock, Curr. Infect. Dis. Rep., 13, 416, 10.1007/s11908-011-0200-1 · DOI
- Pontikis, 2014, Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria, Int. J. Antimicrob. Agents, 43, 52, 10.1016/j.ijantimicag.2013.09.010 · DOI · Paper page
- Barcenilla, 2007, Optimal management therapy for Pseudomonas aeruginosa ventilator-associated pneumonia: An observational, multicenter study comparing monotherapy with combination antibiotic therapy, Crit. Care Med., 35, 1888, 10.1097/01.CCM.0000275389.31974.22 · DOI · Paper page
- Carlier, 2013, Meropenem and piperacillin/tazobactam prescribing in critically ill patients: Does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used?, Crit. Care Lond. Engl., 17, R84, 10.1186/cc12705 · DOI · Paper page
- Carlier, 2014, Extended versus bolus infusion of meropenem and piperacillin: A pharmacokinetic analysis, Minerva Anestesiol., 80, 1302
- Taccone, 2012, Optimal Meropenem Concentrations To Treat Multidrug-Resistant Pseudomonas aeruginosa Septic Shock, Antimicrob. Agents Chemother., 56, 2129, 10.1128/AAC.06389-11 · DOI
- Kuti, 2003, Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem, J. Clin. Pharmacol., 43, 1116, 10.1177/0091270003257225 · DOI · Paper page
- Kothekar, 2020, Clinical pharmacokinetics of 3-h extended infusion of meropenem in adult patients with severe sepsis and septic shock: Implications for empirical therapy against Gram-negative bacteria, Ann. Intensive Care, 10, 4, 10.1186/s13613-019-0622-8 · DOI
- Nasomsong, W., Nulsopapon, P., Changpradub, D., Pungcharoenkijkul, S., Hanyanunt, P., Chatreewattanakul, T., and Santimaleeworagun, W. (2022). Optimizing Doses of Ceftolozane/Tazobactam as Monotherapy or in Combination with Amikacin to Treat Carbapenem-Resistant Pseudomonas aeruginosa. Antibiotics, 11. · DOI
- Gatti, 2021, Ceftolozane/tazobactam exposure in critically ill patients undergoing continuous renal replacement therapy: A PK/PD approach to tailor dosing, J. Antimicrob. Chemother., 76, 199, 10.1093/jac/dkaa416 · DOI
- Ruiz, 2020, Ceftolozane/Tazobactam Dosing Requirements Against Pseudomonas aeruginosa Bacteremia, Dose-Response Publ. Int. Hormesis Soc., 18, 1559325819885790
- Xiao, 2016, Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia, J. Clin. Pharmacol., 56, 56, 10.1002/jcph.566 · DOI
- Lodise, 2007, Piperacillin-tazobactam for Pseudomonas aeruginosa infection: Clinical implications of an extended-infusion dosing strategy, Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am., 44, 357, 10.1086/510590 · DOI · Paper page
- Bauer, 2013, Extended-infusion cefepime reduces mortality in patients with Pseudomonas aeruginosa infections, Antimicrob. Agents Chemother., 57, 2907, 10.1128/AAC.02365-12 · DOI
- Abrar, 2019, The pharmacodynamics of prolonged infusion blactams for the treatment of Pseudomonas aeruginosa infections: A systematic review, Clin. Ther., 41, 2397, 10.1016/j.clinthera.2019.09.010 · DOI
- Dulhunty, 2015, A Multicenter Randomized Trial of Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis, Am. J. Respir. Crit. Care Med., 192, 1298, 10.1164/rccm.201505-0857OC · DOI · Paper page
- Shiu, 2013, Continuous versus intermittent infusions of antibiotics for the treatment of severe acute infections, Cochrane Database Syst. Rev., 2013, CD008481
- Roberts, 2009, A systematic review on clinical benefits of continuous administration of beta-lactam antibiotics, Crit. Care Med., 37, 2071, 10.1097/CCM.0b013e3181a0054d · DOI · Paper page
- Kasiakou, 2005, Continuous versus intermittent intravenous administration of antibiotics: A meta-analysis of randomised controlled trials, Lancet Infect. Dis., 5, 581, 10.1016/S1473-3099(05)70218-8 · DOI · Paper page
- Sulaiman, 2016, Beta-Lactam Infusion in Severe Sepsis (BLISS): A prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis, Intensive Care Med., 42, 1535, 10.1007/s00134-015-4188-0 · DOI · Paper page
- Dulhunty, 2013, Continuous infusion of beta-lactam antibiotics in severe sepsis: A multicenter double-blind, randomized controlled trial, Clin. Infect. Dis., 56, 236, 10.1093/cid/cis856 · DOI · Paper page
- Chytra, 2012, Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: A randomized open-label controlled trial, Crit. Care, 16, R113, 10.1186/cc11405 · DOI · Paper page
- Li, 2021, Short-course versus long-course antibiotic treatment in patients with uncomplicated gram-negative bacteremia: A systematic review and meta-analysis, J. Clin. Pharm. Ther., 46, 173, 10.1111/jcpt.13277 · DOI
- Haddad, 2022, Duration of antibiotic therapy in Gram-negative infections with a particular focus on multidrug-resistant pathogens, Curr. Opin. Infect. Dis., 10, 1097
- Babich, 2022, Duration of Treatment for Pseudomonas aeruginosa Bacteremia: A Retrospective Study, Infect. Dis. Ther., 11, 1505
- Fabre, 2019, Antibiotic Therapy for Pseudomonas aeruginosa Bloodstream Infections: How Long Is Long Enough?, Clin. Infect. Dis., 69, 2011, 10.1093/cid/ciz223 · DOI
- Olearo, 2020, Optimal Treatment Duration of Pseudomonas aeruginosa Infections in Allogeneic Hematopoietic Cell Transplant Recipients, Open Forum Infect. Dis., 7, ofaa246, 10.1093/ofid/ofaa246 · DOI
- Chastre, 2003, Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: A randomized trial, JAMA, 290, 2588, 10.1001/jama.290.19.2588 · DOI · Paper page
- Maharjan, 2022, Isolation and Characterization of Lytic Bacteriophage Against Multi-drug Resistant Pseudomonas aeruginosa, J. Nepal Health Res. Counc., 19, 717
- Dion, 2020, Phage diversity, genomics and phylogeny, Nat. Rev. Microbiol., 18, 125, 10.1038/s41579-019-0311-5 · DOI · Paper page
- Waters, 2017, Phage therapy is highly effective against chronic lung infections with Pseudomonas aeruginosa, Thorax, 72, 666, 10.1136/thoraxjnl-2016-209265 · DOI · Paper page
- Fong, 2017, Activity of Bacteriophages in Removing Biofilms of Pseudomonas aeruginosa Isolates from Chronic Rhinosinusitis Patients, Front. Cell. Infect. Microbiol., 7, 418, 10.3389/fcimb.2017.00418 · DOI · Paper page
- Guo, 2017, A Novel Antimicrobial Endolysin, LysPA26, against Pseudomonas aeruginosa, Front. Microbiol., 8, 293, 10.3389/fmicb.2017.00293 · DOI · Paper page
- Cook, 2021, INfrastructure for a PHAge REference Database: Identification of Large-Scale Biases in the Current Collection of Cultured Phage Genomes, PHAGE, 2, 214, 10.1089/phage.2021.0007 · DOI · Paper page
- Nordstrom, 2022, Genomic characterization of lytic bacteriophages targeting genetically diverse Pseudomonas aeruginosa clinical isolates, iScience, 25, 104372, 10.1016/j.isci.2022.104372 · DOI
- Cafora, 2019, Phage therapy against Pseudomonas aeruginosa infections in a cystic fibrosis zebrafish model, Sci. Rep., 9, 1527, 10.1038/s41598-018-37636-x · DOI · Paper page
- Jennes, 2017, Use of bacteriophages in the treatment of colistin-only-sensitive Pseudomonas aeruginosa septicaemia in a patient with acute kidney injury—A case report, Crit. Care, 21, 129, 10.1186/s13054-017-1709-y · DOI · Paper page
- Bach, 2022, Filamentous bacteriophage delays healing of Pseudomonas-infected wounds, Cell Rep. Med., 3, 100656, 10.1016/j.xcrm.2022.100656 · DOI
- Wright, 2009, A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy, Clin. Otolaryngol., 34, 349, 10.1111/j.1749-4486.2009.01973.x · DOI · Paper page
- Rhoads, 2009, Bacteriophage therapy of venous leg ulcers in humans: Results of a phase I safety trial, J. Wound Care, 18, 237, 10.12968/jowc.2009.18.6.42801 · DOI · Paper page
- Rubalskii, E., Ruemke, S., Salmoukas, C., Boyle, E.C., Warnecke, G., Tudorache, I., Shrestha, M., Schmitto, J.D., Martens, A., and Rojas, S.V. (2020). Bacteriophage Therapy for Critical Infections Related to Cardiothoracic Surgery. Antibiotics, 9. · DOI
- Oechslin, 2017, Synergistic Interaction Between Phage Therapy and Antibiotics Clears Pseudomonas aeruginosa Infection in Endocarditis and Reduces Virulence, J. Infect. Dis., 215, 703
- Holger, 2022, Bacteriophage-antibiotic combination therapy for multidrug-resistant Pseudomonas aeruginosa: In vitro synergy testing, J. Appl. Microbiol., 133, 1636, 10.1111/jam.15647 · DOI
- Chan, 2018, Phage treatment of an aortic graft infected with Pseudomonas aeruginosa, Evol. Med. Public Health, 2018, 60, 10.1093/emph/eoy005 · DOI · Paper page
- Duplessis, 2018, Refractory Pseudomonas Bacteremia in a 2-Year-Old Sterilized by Bacteriophage Therapy, J. Pediatr. Infect. Dis. Soc., 7, 253, 10.1093/jpids/pix056 · DOI
- Simner, 2022, Combination of phage therapy and cefiderocol to successfully treat Pseudomonas aeruginosa cranial osteomyelitis, JAC-Antimicrob. Resist., 4, dlac046, 10.1093/jacamr/dlac046 · doi:10.1093/jacamr/dlac046
- Khawaldeh, 2011, Bacteriophage therapy for refractory Pseudomonas aeruginosa urinary tract infection, J. Med. Microbiol., 60, 1697, 10.1099/jmm.0.029744-0 · doi:10.1099/jmm.0.029744-0
- Racenis, 2022, Use of Phage Cocktail BFC 1.10 in Combination With Ceftazidime-Avibactam in the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Femur Osteomyelitis-A Case Report, Front. Med., 9, 851310, 10.3389/fmed.2022.851310 · doi:10.3389/fmed.2022.851310
- Aslam, 2019, Early clinical experience of bacteriophage therapy in 3 lung transplant recipients, Am. J. Transplant., 19, 2631, 10.1111/ajt.15503 · DOI · Paper page
- Chen, 2022, Bacteriophage therapy for empyema caused by carbapenem-resistant Pseudomonas aeruginosa, Biosci. Trends, 16, 158, 10.5582/bst.2022.01147 · doi:10.5582/bst.2022.01147
- Hoggarth, 2019, Mechanistic research holds promise for bacterial vaccines and phage therapies for Pseudomonas aeruginosa, Drug Des. Devel. Ther., 13, 909, 10.2147/DDDT.S189847 · DOI
- Hart, 2022, Vaccination to Prevent Pseudomonas aeruginosa Bloodstream Infections, Front. Microbiol., 13, 870104, 10.3389/fmicb.2022.870104 · DOI
- Adlbrecht, 2020, Efficacy, immunogenicity, and safety of IC43 recombinant Pseudomonas aeruginosa vaccine in mechanically ventilated intensive care patients—A randomized clinical trial, Crit. Care, 24, 74, 10.1186/s13054-020-2792-z · doi:10.1186/s13054-020-2792-z
- Hauser, 2009, The type III secretion system of Pseudomonas aeruginosa: Infection by injection, Nat. Rev. Microbiol., 7, 654, 10.1038/nrmicro2199 · DOI · Paper page
- Sawa, 2014, Association between Pseudomonas aeruginosa type III secretion, antibiotic resistance, and clinical outcome: A review, Crit. Care Lond. Engl., 18, 668, 10.1186/s13054-014-0668-9 · DOI
- Luyt, 2012, Safety and pharmacokinetics of an anti-PcrV PEGylated monoclonal antibody fragment in mechanically ventilated patients colonized with Pseudomonas aeruginosa: A randomized, double-blind, placebo-controlled trial, Crit. Care Med., 40, 2320, 10.1097/CCM.0b013e31825334f6 · DOI · Paper page
- Song, 2012, PcrV antibody-antibiotic combination improves survival in Pseudomonas aeruginosa-infected mice, Eur. J. Clin. Microbiol. Infect. Dis., 31, 1837, 10.1007/s10096-011-1509-2 · DOI
- Lindorfer, 2001, Targeting of Pseudomonas aeruginosa in the Bloodstream with Bispecific Monoclonal Antibodies, J. Immunol., 167, 2240, 10.4049/jimmunol.167.4.2240 · DOI
- Lee, 2015, The hierarchy quorum sensing network in Pseudomonas aeruginosa, Protein Cell, 6, 26, 10.1007/s13238-014-0100-x · DOI · Paper page
- Nguyen, 2008, Pyopneumagen Group Quorum-sensing activity and related virulence factor expression in clinically pathogenic isolates of Pseudomonas aeruginosa, Clin. Microbiol. Infect., 14, 337, 10.1111/j.1469-0691.2007.01925.x · DOI
- Wu, 2004, Synthetic furanones inhibit quorum-sensing and enhance bacterial clearance in Pseudomonas aeruginosa lung infection in mice, J. Antimicrob. Chemother., 53, 1054, 10.1093/jac/dkh223 · DOI · Paper page
- Hoffmann, 2007, Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(−/−) mice, Antimicrob. Agents Chemother., 51, 3677, 10.1128/AAC.01011-06 · DOI · Paper page
- Adonizio, 2008, Inhibition of quorum sensing-controlled virulence factor production in Pseudomonas aeruginosa by South Florida plant extracts, Antimicrob. Agents Chemother., 52, 198, 10.1128/AAC.00612-07 · DOI · Paper page
- Smyth, 2010, Garlic as an inhibitor of Pseudomonas aeruginosa quorum sensing in cystic fibrosis—A pilot randomized controlled trial, Pediatr. Pulmonol., 45, 356, 10.1002/ppul.21193 · DOI · Paper page
- Cotter, 2013, Bacteriocins—A viable alternative to antibiotics?, Nat. Rev. Microbiol., 11, 95, 10.1038/nrmicro2937 · DOI · Paper page
- Ali, 2011, Antagonistic effect of bacteriocin against urinary catheter associated Pseudomonas aeruginosa biofilm, N. Am. J. Med. Sci., 3, 367
- Snopkova, 2020, Prevalence of bacteriocins and their co-association with virulence factors within Pseudomonas aeruginosa catheter isolates, Int. J. Med. Microbiol., 310, 151454, 10.1016/j.ijmm.2020.151454 · doi:10.1016/j.ijmm.2020.151454
Cited by
Alshaybawee, M. R., Asgari, S., Ghadersoltani, P., Mehrabian, A., & Saniee, P. (2025) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-025-04778-1 · Cited by 8
Metadata
- Authors
- Zakhour, J., Sharara, S. L., Hindy, J.-R., Haddad, S. F., & Kanj, S. S.
- Venue
- Antibiotics
- Publisher
- MDPI AG
- Published
- 2022-10-18
- Volume
- 11
- Issue
- 10
- Pages
- 1432
- ISSN
- 2079-6382
- Cited by
- 48
- References
- 9
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antimicrobial Treatment of Pseudomonas aeruginosa Severe Sepsis. https://app.cochat.ai/papers/10.3390/antibiotics11101432
- The paper
- Zakhour, J., Sharara, S. L., Hindy, J.-R., Haddad, S. F., & Kanj, S. S. (2022). Antimicrobial Treatment of Pseudomonas aeruginosa Severe Sepsis. Antibiotics. https://doi.org/10.3390/antibiotics11101432
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.